Japan's Eisai Links With Anaeropharma Science For Cancer Agent Study
This article was originally published in PharmAsia News
Executive SummaryJapan's Eisai and Anaeropharma Science say they have reached research and licensing agreements for the use of a new cancer agent, APS001
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.